Cytotherapy

Aims and Scope

Cytotherapy, the official journal of the International Society of Cell and Gene Therapy (ISCT), publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell and gene therapy. In addition to Short Reports and Full-Length Articles, the journal also accepts Editorials on emerging trends and potential controversies in the field, and Review articles summarizing important areas of cell and gene therapy research that are topical and/or challenge existing paradigms in the field.

Cytotherapy considers manuscripts exploring the following topics:

Gene, cell (includes stem cells and iPSCs) and EV-based therapies
Regulatory frameworks and policy issues in CGT
Novel and innovative results from basic, translational, and clinical studies in CGT
Important advances in cell/gene-based product manufacturing,
commercialization and patient access
Clinical studies evaluating the safety and efficacy of cell and gene therapies

Cytotherapy does not publish manuscripts on the following topics:

Case studies unless they are of unusual significance to the field.
Basic/translational studies exploring the role of lncRNAs, circRNAs, and miRNAs in disease pathophysiology
Studies describing signaling pathways implicated in cancer

Mission Statement

To be the premier cell and gene therapy translation journal.

Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing (Qayed et al., 2022)
Registered clinical trials investigating treatment with cell-derived extracellular vesicles: a scoping review (Duong et al., 2023)
The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer (Klingemann, 2023)
Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products (Cuende et al., 2022)
Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering (Si et al., 2023)
Adipose-derived stem cells applied in skin diseases, wound healing and skin defects: a review (Schneider et al., 2023)
Dental pulp stem cell-derived extracellular matrix: autologous tool boosting bone regeneration (Alksne et al., 2022)
Prevention of chronic diabetic complications in type 1 diabetes by co-transplantation of umbilical cord mesenchymal stromal cells and autologous bone marrow: a pilot randomized controlled open-label clinical study with 8-year follow-up (Wu et al., 2022)
International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products (Ikonomou et al., 2023)
Mechanism for the attenuation of neutrophil and complement hyperactivity by MSC exosomes (Loh et al., 2022)
Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late? (Kirkham et al., 2023)
A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture (O'Reilly et al., 2023)
Targeting of low ALK antigen density neuroblastoma using AND logic- gate engineered CAR-T cells (Halliwell et al., 2023)
Identification of marker genes to monitor residual iPSCs in iPSC-derived products (Lemmens et al., 2023)
Small extracellular vesicles from mesenchymal stromal cells: the next therapeutic paradigm for musculoskeletal disorders (Teo et al., 2023)
Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness (Lau et al., 2023)
CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma (Schomer et al., 2022)
Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells (Gurney et al., 2022)
Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma (Thielen et al., 2022)
Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion (Srinivasan et al., 2022)
Proteomics profile of mesenchymal stromal cells and extracellular vesicles in normoxic and hypoxic conditions (Braga et al., 2022)
Sirtuin 6 regulates macrophage polarization to alleviate sepsis-induced acute respiratory distress syndrome via dual mechanisms dependent on and independent of autophagy (Wang et al., 2022)

Submit a Manuscript

Cytotherapy publishes original papers, reviews, novel hypotheses, short communications, book reviews and editorials. Submitted manuscripts will be reviewed by at least two reviewers. Authors will be notified within 30 working days of receipt, whether the manuscript is accepted, requires revision, or is rejected. All manuscripts will be published within 5 months from the date of acceptance.

Submit Now

Journal Leadership

Editor-in-Chief

Edwin M. Horwitz
MD, PhD
Emory University School of Medicine
United States

Managing Editor

Kenneth W. Witwer
PhD
Johns Hopkins University
United States

Commissioning Editor

Patrick J. Hanley
PhD
Children's National Hospital
United States

Associate Editors

	Shin Kawamata MD, PhD Cyto-Facto Japan		Sai Kiang Lim PhD Paracrine Therapeutics Pte Ltd Singapore
	George Muschler PhD Cleveland Clinic United States		Anna Pasetto PhD Oslo University Hospital Norway
	Susan Prockop MD Boston Children's Hospital United States		Qasim Rafiq MEng, PhD University College London United Kingdom
	Sowmya Viswanathan PhD University Health Network Canada